Oncolytic virus clinical trial opens for patients with advanced breast cancer

City of Hope recently announced the opening of a phase 1 clinical trial for experimental therapy in patients with triple negative metastatic breast cancer. The trial is the first human analysis of the use of an oncolytic virus, which is a cancer killer virus, to treat patients.

City of Hope researchers have created a genetically engineered therapy, CF33-hNIS-antiPDL1, from the naturally occurring oncolytic virus. The therapy aims to infect, reproduce and kill cancer cells while leaving healthy cells intact.

“The study is designed to determine the safety and the optimal biological dose that can induce an immune response in triple negative breast cancer tumors,” said Dr. Yuan Yuan, associate professor in the department of medical oncology and research City of Hope Therapeutics and Principal Investigator. of the trial, in a press release. “Currently approved therapies fail to cure this aggressive type of breast cancer, which often becomes resistant to chemotherapy. Clinical trials like this are looking for lasting answers and a better quality of life for patients. “

The trial is expected to examine whether the therapy is safe and effective in 78 patients whose disease has progressed beyond standard chemotherapy. It is expected to last three years and recruitment is currently open for patients. The treatment will be given in three cycles of six doses by direct injection into the tumor.

“It is an exciting time in immuno-oncology. Preclinical research has shown that this oncolytic virus can direct the destruction of cancers and stimulate the immune system to enable further destruction of cancers, ”said Dr Yuman Fong, Sangiacomo Family Chair in Surgical Oncology at City of Hope, who developed the CF33, in a press release. “This trial is an important step forward. “

For more information on cancer updates, research and education, be sure to subscribe to CURE® newsletters here.

Comments are closed.